SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-356184
Filing Date
2021-12-14
Accepted
2021-12-14 07:17:55
Documents
12
Period of Report
2021-12-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K d52326d8k.htm   iXBRL 8-K 24457
  Complete submission text file 0001193125-21-356184.txt   143281

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA gbt-20211214.xsd EX-101.SCH 2913
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE gbt-20211214_lab.xml EX-101.LAB 17374
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gbt-20211214_pre.xml EX-101.PRE 10968
5 EXTRACTED XBRL INSTANCE DOCUMENT d52326d8k_htm.xml XML 3254
Mailing Address 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080
Business Address 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080 650741-7700
Global Blood Therapeutics, Inc. (Filer) CIK: 0001629137 (see all company filings)

IRS No.: 274825712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37539 | Film No.: 211489678
SIC: 2834 Pharmaceutical Preparations